Lord, Abbett & Co
KYNB

Lord, Abbett & Co’s Kyntra Bio KYNB Stock Holding History

Lord, Abbett & Co’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,951
Closed -$8.09M – 782
2019
Q1 		$8.09M Sell
5,951
-194
-3% -$263K 0.03% 585
2018
Q4 		$7.11M Sell
6,145
-14,300
-70% -$16.1M 0.03% 594
2018
Q3 		$31.1M Sell
20,445
-4,335
-17% -$6.68M 0.09% 378
2018
Q2 		$38.8M Buy
24,780
+1,608
+7% +$2.1M 0.11% 287
2018
Q1 		$26.8M Buy
23,172
+4,811
+26% +$6.34M 0.08% 387
2017
Q4 		$21.8M Sell
18,361
-2,180
-11% -$2.73M 0.06% 453
2017
Q3 		$27.6M Buy
+20,541
New +$21.6M 0.08% 392

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Lord, Abbett & Co's KYNB Position: Q2 2019 in Review

Lord, Abbett & Co sold out of Kyntra Bio (KYNB) in Q2 2019, closing a stake of 5,951 shares — an estimated $8.09M sold.

Lord, Abbett & Co first reported a position in KYNB in Q3 2017 and held it in 7 quarters. The position peaked at $38.8M in Q2 2018. 190 funds tracked by Wall St. Rank hold KYNB as of Q2 2019.

  • Lord, Abbett & Co reported no remaining Kyntra Bio position as of Q2 2019 after selling out during the quarter.
  • Lord, Abbett & Co sold 5,951 Kyntra Bio shares in Q2 2019, an estimated $8.09M.
  • Lord, Abbett & Co first reported a position in Kyntra Bio in Q3 2017 and held it in 7 quarters.
  • Lord, Abbett & Co's Kyntra Bio position peaked at $38.8M in Q2 2018.
  • 190 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2019.

Based on Lord, Abbett & Co's 13F filing for Q2 2019, filed 14 Aug 2019.